Neil Gregory Almstead

Neil Gregory Almstead (CTO) sold 23,749 shares at $80.90 avg for $1.9M via scheduled 10b5-1 plan

Neil Gregory Almstead, Chief Technical Operations Officer, executed 2 separate sales totaling 23,749 shares for $1,921,378.29 on 2026-06-22 pursuant to a pre-arranged 10b5-1 trading plan adopted on 2025-11-11. His non-derivative holdings decreased 28.3% from 83,886 shares to 60,137 shares; however, he retains 23,751 stock options (derivative securities) in Table II. The stock has appreciated +22.7% over 30 days and +26.0% over 90 days, currently trading at $84.41, which is -3.5% from its 52-week high of $87.50. At PTCT specifically, his prior 5 open-market trades show 30-day returns ranging from -7.4% to -5.4%, with the two measurable 90-day outcomes at -16.7% and -15.5%. This transaction is scheduled, not discretionary, under the 10b5-1 framework.

Chief Technical Ops Officer Almstead sells 52,003 shares at $69.04 avg; PTCT stock down 21.4% from 52-week high despite +114.5% annual revenue growth.

Neil Gregory Almstead executed 3 separate sales totaling 52,003 shares for $3,590,242.77 on 2026-04-01, reducing his holdings from 112,140 to 60,137 shares (-46.4%). The transactions occurred at prices ranging from $68.89 to $70.30, with a blended average of $69.04—notably above the current price of $67.77 but well below the 52-week high of $86.25. His prior 5 trades at PTCT (all sales on 2025-11-25) each posted negative 90-day returns (-17.4%, -15.5%, -16.7%, -14.7%, -15.4%), and his broader cross-ticker history shows a 100% well-timed rate on 20 prior sells with an average 90-day return of -15.8%. Despite strong fundamentals—revenue of $211,007,000.00 and annual growth of +114.5%—the stock has declined 11.7% over 90 days and sits 21.4% below its annual peak. The consistent pattern of prior well-timed exits at this ticker, combined with this substantial reduction in an executive officer's holdings at a price level since breached downward, warrants attention to the disconnect between reported financial momentum and the stock's price trajectory.

Chief Technical Ops Officer sells 35.6K shares of PTCT for $2.9M at blended $80.18 on 2025-11-24

Almstead Neil Gregory, Chief Technical Operations Officer of PTC Therapeutics, executed 5 separate sales totaling 35,572 shares for $2,852,030.56 on 2025-11-24 at prices ranging from $80.14 to $80.19. This represents a 26.1% reduction in his pre-transaction holdings (from 136,197 to 100,625 shares). The sales occurred when the stock was trading near its 52-week high of $86.25 and during a period of strong momentum (73.2% gain over 90 days, 28.6% over 30 days). Given that PTC Therapeutics posted full-year net income that was negative despite recent quarterly profitability ($15.9M net income in the latest quarter but annual revenue declined 14.0% year-over-year), the insider's substantial reduction in holdings warrants attention to whether this reflects management confidence or capital allocation priorities. His cross-ticker track record shows 20 prior sells with an average 30-day return of +2.6%, though prior trades at PTCT have outcomes not yet measurable.

Chief Technical Ops Officer Neil Gregory sells 71,928 shares ($6.0M) across 19 transactions at PTCT on 2025-11-25, reducing holdings by 41.7%

Neil Gregory, CHIEF TECHNICAL OPS OFFICER at PTC THERAPEUTICS, executed 19 separate sales totaling 71,928 shares for $6,001,932.05 on 2025-11-25, with a blended average price of $83.44. This sale reduced his holdings from 172,553 shares to 100,625 shares, a net reduction of 41.7%. The timing coincides with PTCT trading at the 52-week high ($86.25 current price at +0.0% from 52-week high), and follows a sharp 28.6% 30-day gain and 73.2% 90-day gain. Notably, the insider's cross-ticker sell track record shows a 90d well-timed rate of 0.00%, and his 5 most recent PTCT trades (all on 2025-11-24) have outcomes not yet measurable. The company's fundamentals show annual revenue declined 14.0% year-over-year and net income was negative on a full-year basis, despite current profitability in the latest quarter ($15.9M net income on $211.0M revenue).

Chief Technical Ops Officer sold 55,000 shares ($3.6M) across 6 transactions at blended avg $66.05; reduces stake by 35.3% to 100.6K shares remaining.

Almstead Neil Gregory, Chief Technical Ops Officer at PTC Therapeutics, executed 6 separate sales totaling 55,000 shares for $3,632,976.72 on 2025-10-03 at prices ranging from $65.45 to $67.16. This represents a material 35.3% reduction in his shareholding, from 155.6K shares to 100.6K shares. The sales occurred near PTC's 52-week high of $65.37 (blended price of $66.05 is +0.1% above the 52-week high), following a +31.1% gain over the prior 90 days. Notably, this insider's prior 5 sales at PTCT all resulted in positive 90-day returns (stock rose after each sale), indicating a consistent pattern of selling before continued ascents; the company is currently unprofitable with -14.0% annual revenue growth, yet the stock has appreciated sharply recently, creating potential disconnection between fundamentals and price momentum.

CTO Neil Almstead sells 71,610 shares ($3.7M) of PTCT, reducing stake by 94.0% across 6 transactions on 2024-12-02

Almstead, Chief Technical Operations Officer, executed 6 separate sales totaling 71,610 shares for $3,727,957.62 on 2024-12-02, with a blended average price of $52.06. This represents a 94.0% reduction in his pre-transaction holdings from 76,186 shares to 4,576 shares. The timing occurs within the company's 52-week trading range of $23.02–$52.07, with the stock at the 52-week high ($52.07 is 0.02% above transaction prices), and follows a strong 30-day rally of +23.4% and 90-day gain of +57.8%. PTC Therapeutics is a $3.8B market-cap biopharma company with growing revenue (+34.2% annual growth to $196.8M latest quarter) but currently unprofitable with full-year net income of $-106.7M. The near-complete liquidation of Almstead's position warrants examination of whether this reflects pre-planned capital reallocation or a shift in the insider's assessment of the company's prospects.